Provectus Biopharmaceuticals Inc (PVCT)
0.1985
0.00 (0.00%)
USD |
OTCM |
Apr 26, 15:50
Provectus Biopharmaceuticals Cash from Operations (TTM): -2.572M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -2.572M |
September 30, 2023 | -2.766M |
June 30, 2023 | -2.813M |
March 31, 2023 | -3.073M |
December 31, 2022 | -3.042M |
September 30, 2022 | -0.6647M |
June 30, 2022 | -0.6638M |
March 31, 2022 | -0.492M |
December 31, 2021 | -1.013M |
September 30, 2021 | -3.593M |
June 30, 2021 | -4.221M |
March 31, 2021 | -4.483M |
December 31, 2020 | -4.086M |
September 30, 2020 | -4.267M |
June 30, 2020 | -4.317M |
March 31, 2020 | -4.840M |
December 31, 2019 | -6.190M |
September 30, 2019 | -5.861M |
June 30, 2019 | -5.287M |
March 31, 2019 | -5.531M |
December 31, 2018 | -5.205M |
September 30, 2018 | -6.861M |
June 30, 2018 | -8.236M |
March 31, 2018 | -8.859M |
December 31, 2017 | -10.35M |
Date | Value |
---|---|
September 30, 2017 | -11.89M |
June 30, 2017 | -14.60M |
March 31, 2017 | -17.11M |
December 31, 2016 | -21.94M |
September 30, 2016 | -22.89M |
June 30, 2016 | -22.11M |
March 31, 2016 | -21.28M |
December 31, 2015 | -17.41M |
September 30, 2015 | -16.62M |
June 30, 2015 | -15.80M |
March 31, 2015 | -15.18M |
December 31, 2014 | -13.85M |
September 30, 2014 | -11.85M |
June 30, 2014 | -11.22M |
March 31, 2014 | -9.767M |
December 31, 2013 | -9.892M |
September 30, 2013 | -11.04M |
June 30, 2013 | -10.51M |
March 31, 2013 | -11.45M |
December 31, 2012 | -11.26M |
September 30, 2012 | -11.87M |
June 30, 2012 | -13.41M |
March 31, 2012 | -15.74M |
December 31, 2011 | -17.20M |
September 30, 2011 | -17.24M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-6.190M
Minimum
Dec 2019
-0.492M
Maximum
Mar 2022
-3.381M
Average
-3.593M
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
Insmed Inc | -536.25M |
NeuroMetrix Inc | -6.085M |
Intra-Cellular Therapies Inc | -124.20M |
Rhythm Pharmaceuticals Inc | -136.16M |
Amylyx Pharmaceuticals Inc | 11.92M |